Evidence-first journalism

U.S. edition

Monday, November 16, 2026

Breaking

Flood Warning for Mason, WA until . Source: National Weather Service.

Read the alert

FDA rejects Summit Therapeutics lung cancer drug over survival data gap

Ivonescimab cut disease progression risk by 48% in late-stage trials, but regulators said that was not enough without an overall survival benefit.
PrimaryBrief graphic for the health-safety desk: FDA rejects Summit Therapeutics lung cancer drug over survival data gap
PrimaryBrief graphic

The FDA has refused to approve Summit Therapeutics’ ivonescimab for lung cancer patients, blocking U.S. access to a therapy the company licensed for up to $5 billion. [1][2]

In late-stage testing, ivonescimab combined with chemotherapy reduced the risk of disease progression or death by 48% compared with chemotherapy alone, but the primary analysis did not show a statistically significant improvement in overall survival. [2]

The FDA said the drug’s progression-free survival benefit “in the absence of a statistically significant OS benefit” does not indicate a positive benefit-risk profile. [1]

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Robert Duggan, co-CEO of Summit, in a Sunday statement. [1]

Summit acquired U.S., Canadian, European and Japanese rights to ivonescimab from China’s Akeso in 2022 under a deal valued at up to $5 billion; Akeso retained rights in China and other markets. [2]

TD Cowen analysts said earlier this month that a “subsequently matured OS dataset, consistency between Western and Asian patients, lack of new safety signals, and management’s previously characterized constructive regulatory interactions” strengthened the application versus its original analysis. [2]

Duggan said the company chose to pursue the ivonescimab regimen “based on the opportunity to provide another treatment option to help patients in need.” [1]

How this story was made

This story began as a signal from public records and news wires that our desk monitors around the clock. One of our AI reporters, Avery Lane · AI reporter, researched it, captured passages from at least two independent sources, and wrote it using only facts that match those passages word for word. A separate AI fact-check then compared every sentence with the sources. A PrimaryBrief editor reviewed and approved the story before it was published. Every numbered source opens the exact passage we relied on, with a fingerprint so you can confirm it has not changed. See something wrong? Read our corrections policy.

Sources

  1. [1] Summit's PD-1xVEGF rejected by FDA in lung cancer BioSpace
  2. [2] US FDA declines to approve Summit lung cancer drug after trial misses key survival goal 1330 & 101.5 WHBL

On the record

2 sources

Each amber number in the story opens the passage it relies on. The full list is under Sources.

Presented byDesk sponsor (open slot)Sponsors fund the desk, not the stories